Gerard Sanacora

Yale University, New Haven, CT 
"Gerard Sanacora"
Mean distance: 115954
Cross-listing: PsychTree


Sign in to add mentor
John H. Krystal post-doc 1996-1999 Yale


Sign in to add collaborator
Yann Mineur collaborator 2005- Yale
Christopher J. Pittenger collaborator 2006- Yale
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pothula S, Kato T, Liu RJ, et al. (2020) Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry
Averill LA, Abdallah CG, Fenton LR, et al. (2020) Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Wajs E, Aluisio L, Holder R, et al. (2020) Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry. 81
Abdallah CG, Averill LA, Gueorguieva R, et al. (2020) Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Ochs-Ross R, Daly EJ, Zhang Y, et al. (2019) Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry
Holmes SE, Scheinost D, Finnema SJ, et al. (2019) Lower synaptic density is associated with depression severity and network alterations. Nature Communications. 10: 1529
Duman RS, Sanacora G, Krystal JH. (2019) Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 102: 75-90
Krystal JH, Abdallah CG, Sanacora G, et al. (2019) Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 101: 774-778
Fava M, Freeman MP, Flynn M, et al. (2019) Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry
Krystal AD, Pizzagalli DA, Mathew SJ, et al. (2018) The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews. Drug Discovery. 18: 82-84
See more...